ThePeptide.expert
Database

Peptide profiles.

Filter by category, search by name. Each profile is graded on a five-tier evidence scale.

11 profiles

Sermorelin

GHRH(1-29) / Geref

FDA approved
injectable
Evidence

The original FDA-approved GHRH analogue. Stimulates natural GH production through your own pituitary gland. Most natural approach to growth hormone optimization available.

Tesamorelin

Egrifta / Stabilized GHRH / GHRH analogue

FDA approved
injectable
Evidence

The most clinically validated GHRH analogue available. FDA-approved for visceral fat reduction. Emerging data for cognitive protection in early Alzheimer's and MCI. Widely prescribed off-label for body composition and longevity.

Ipamorelin

Growth Hormone Secretagogue (selective)

Cat 1 — 2026
injectable
Evidence

The most selective GH secretagogue available. Stimulates strong growth hormone release with minimal cortisol or prolactin side effects. Considered the gold standard secretagogue.

MOTS-c

Mitochondrial ORF of 12S rRNA type-c

Cat 1 — 2026
injectable
Evidence

Mitochondria-derived peptide discovered in 2015. Acts as an exercise mimetic by activating the same metabolic pathways triggered by physical activity. Levels naturally decline with age.

GLP-3

Triple-Action Metabolic Compound (RT formulation)

RUO only
injectable
Evidence

A triple-action metabolic research compound combining GLP-1, GLP-2, and GLP-3 receptor activity. Studied for metabolic regulation, gut health, and appetite modulation in preclinical models.

CJC-1295 / Ipamorelin Stack

CJC-Ipa / GH Stack / Secretagogue Combination

Cat 1 — 2026
injectable
Evidence

The most commonly prescribed GH secretagogue combination in US longevity medicine. CJC-1295 provides GHRH stimulation while Ipamorelin provides ghrelin receptor stimulation — two complementary pathways for natural GH optimization.

KLOW Blend

AminoClub KLOW / Cellular Peptide Blend

Cat 1 — 2026
injectable
Evidence

A proprietary AminoClub peptide blend formulated for metabolic optimization, body composition, and longevity. Targets the GH axis, metabolic pathways, and cellular health simultaneously.

Ipamorelin

Growth Hormone Secretagogue (selective) / GHS

Cat 1 — 2026
injectable
Evidence

The most selective growth hormone secretagogue available. Stimulates strong GH release with minimal cortisol or prolactin side effects. Gold standard for GH axis optimization.

GHRP-2

Growth Hormone Releasing Peptide-2 / Pralmorelin

RUO only
injectable
Evidence

Potent GH secretagogue with stronger GH pulse than Ipamorelin but significant cortisol and prolactin elevation. Largely replaced by Ipamorelin in clinical settings.

GHRP-6

Growth Hormone Releasing Peptide-6

RUO only
injectable
Evidence

Early GH secretagogue notable for strong appetite stimulation via ghrelin pathway. Studied for cachexia and muscle wasting. Also has gastroprotective properties similar to BPC-157.

AOD-9604

Anti-Obesity Drug 9604 / hGH fragment 177-191

Cat 1 — 2026
injectableoral
Evidence

Fat-burning fragment of human growth hormone. Stimulates lipolysis without the anabolic or glucose effects of full GH. Completed Phase IIb human trials. Program paused vs GLP-1 competition.